Spots Global Cancer Trial Database for Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea
Official Title: Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study ID: NCT03271554
Conditions
Interventions
Study Description
Brief Summary: Alectinib was approved by the Ministry of Food and Drug Safety (MFDS) in Korea in Oct 2016. The purpose of this registry is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and effectiveness of the new drug so that the regulatory authority can manage the marketing approval properly.
Detailed Description:
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Inje University Busan Paik Hospital, Busan, , Korea, Republic of
Dong-A University Hospital, Busan, , Korea, Republic of
Pusan National University Hospital, Busan, , Korea, Republic of
Kosin University Gospel Hospital, Busan, , Korea, Republic of
Dongnam Institute of Radiological & Medical Sciences, Busan, , Korea, Republic of
Chungbuk National University Hospital, Cheongju-si, , Korea, Republic of
Kyungpook National University Chilgok Hospital, Daegu, , Korea, Republic of
Keimyung University Dongsan Medical Center, Daegu, , Korea, Republic of
Daegu Catholic University Medical Center, Daegu, , Korea, Republic of
Konyang University Hospital, Daejeon, , Korea, Republic of
Yonsei University Wonju Severance Christian Hospital, Gangwon-do, , Korea, Republic of
Inje University Ilsan Paik Hospital, Gyeonggi-do, , Korea, Republic of
Uijeongbu St. Mary's Hospital, Gyeonggi-do, , Korea, Republic of
CHA Bundang Medical Center, Gyeonggi-do, , Korea, Republic of
Hallym University Sacred Heart Hospital, Gyeonggi-do, , Korea, Republic of
Bucheon St Mary's hospital, Gyeonggi-do, , Korea, Republic of
St. Vincent's Hospital, Gyeonggi-do, , Korea, Republic of
Pusan National University Yangsan Hospital, Gyeongsangnam-do, , Korea, Republic of
Catholic Univ. of Incheon St.Mary's Hospital, Incheon, , Korea, Republic of
Gachon University Gil Medical Center, Incheon, , Korea, Republic of
Inha University Hospital, Incheon, , Korea, Republic of
Chonbuk National University Hospital, Jeollabuk-do, , Korea, Republic of
Chonnam National University Hwasun Hospital, Jeollanam-do, , Korea, Republic of
Inje University, Sanggye-Paik Hospital, Seoul, , Korea, Republic of
Kyung Hee University Hospital, Seoul, , Korea, Republic of
Korea University Anam Hospital, Seoul, , Korea, Republic of
Kangbuk Samsung Hospital, Seoul, , Korea, Republic of
Severance Hospital, Yonsei University, Seoul, , Korea, Republic of
Severance Hospital, Seoul, , Korea, Republic of
Gangdong Kyung Hee University Hospital, Seoul, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Gangnam Severance Hospital, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
Ewha Womans University Mokdong Hospital, Seoul, , Korea, Republic of
Korea University Guro Hospital, Seoul, , Korea, Republic of
Soon Chun Hyang University Hospital; Department of Pulmonology and Allergy, Seoul, , Korea, Republic of
Yonsei University Wonju Severance Christian Hospital, Wonju-Si, , Korea, Republic of
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
